Brief: Resverlogix Corp announces dosing of first two patients in expanded renal and orphan programs
21/07/2016 19:35
July 21 (Reuters) - Resverlogix Corp RVX.TO :
* Results are expected in second half of 2016 from phase 1
study
* Resverlogix announces dosing of first two patients in
expanded renal and orphan programs
Source text for Eikon: urn:newsml:reuters.com:*:nCNW06CCda
Further company coverage: RVX.TO
(Reporting by Parikshit Mishra)
((Parikshit.Mishra@thomsonreuters.com; +91 80 6749 6026;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment